Dual Specificity Protein Phosphatase 1/6 Inhibitor, BCI
The Dual Specificity Protein Phosphatase 1/6 Inhibitor, BCI controls the biological activity of Dual Specificity Protein Phosphatase 1/6. Primarily used for Phosphorylation & Dephosphorylation apps.
A cell-permeable cyclohexylamino-indenone compound that acts as an allosteric inhibitor against substrate binding-induced MAPK phosphatase activity of Dusp1/CL100/HVH1/MKP1/PTPN10 and Dusp6/MKP3/PYST1 (57% and 30% reduction, respectively, of 0.21 and 2.1 µg Erk2-induced OMFP dephosphorylation by 0.21 µg Dusp6) by locking Dusp1 and Dusp6 in their low-activity conformation, while exhibiting little activity toward Cdc25B, DUSP3/VHR, DUSP5, or PTP1B. Shown to effectively enhance cellular Erk phosphorylation in HeLa cells overexpressing human Dusp1 and Dusp6 (EC50 = 11.5 and 12.3 µM, respectively). FGF signaling activation by BCI treatment (5 to 10 µM) during zebrafish embryo development is reported to expand myocardial progenitors population at the expense of other progenitor cell types, resulting in enlarged heart size.
Packaging
Packaged under inert gas
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstiution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Molina, G., et al. 2009. Nat. Chem. Biol.5, 680.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Idiopathic pulmonary fibrosis (IPF) is a progressive terminal lung disease, and therapies aim to block fibrosis. Fibroblast proliferation is controlled by C/EBP-β, microRNA cluster 17-92 (miR17-92), and Erk1/2 mitogen-activated protein kinase. This study assessed the role of miR17-92 in IPF-fibroblast
Meningiomas are the most common primary intracranial tumor with current classification offering limited therapeutic guidance. Here, we interrogated meningioma enhancer landscapes from 33 tumors to stratify patients based upon prognosis and identify novel meningioma-specific dependencies. Enhancers robustly stratified meningiomas into
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
